Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Amgen
- 02 Apr 2022 This trial has been completed in France (End Date: 15 Oct 2011) according to European Clinical Trials Database record.
- 01 Nov 2016 Results published in the American Journal of Gastroenterology
- 22 May 2012 Results presented at Digestive Disease Week 2012.